Ilika Plc and Galvani Bioelectronics enter into collaboration in Bioelectronics Project

Ilika plc
[shareaholic app="share_buttons" id_name="post_below_content"]

Ilika Plc (LON:IKA), a pioneer in materials innovation and solid-state battery technology, announces a two-year collaborative project with Galvani Bioelectronics to develop a solid state battery for miniature medical implants. Ilika’s StereaxTM batteries have a high power density, a long battery life and they can be produced in miniature form, making them particularly suitable for these micro-devices.

This collaboration aims to deliver key components of bioelectronic devices, which have the potential to provide treatments for serious health conditions, through the body’s own nervous system. The £1.0 million development project is supported by funding of £0.7 million, which Ilika will receive from Innovate UK and the Medical Research Council.

Commenting on this grant award, Graeme Purdy, Ilika Plc CEO, said: “This partnership with Galvani Bioelectronics, using Ilika’s lithium-ion Stereax battery technology, may provide the potential to treat diseases that have so far been difficult to manage. Collaborations like this are critical to the delivery of advances in the field of solid state battery development.”

Zeus Capital said:

This morning’s announcement from Ilika, although relatively modest in initial top line impact, has significant commercial implications in the medium to longer term. Galvani was established to advance bioelectronic medicine, an emerging scientific field aimed at using tiny implantable devices to control electrical signals in nerves to treat a range of debilitating chronic diseases. Galvani combines GSK’s world-leading drug discovery and disease biology expertise, with Verily’s expertise in the miniaturisation of low-power electronic devices, data analytics and software development for clinical applications. Veriliy – formerly Google Life Sciences – was set up by Google founders Larry Page and Sergey Brin for the advancement of life sciences. Solid-state battery technology is really currently the only existing low-power source choice for intra-body bioelectronic medical applications for the following reasons:

i. There is no potential for the leakage of harmful liquid electrolytes into the human body chemistry.

ii. Solid-state battery chemistry can be miniaturized to a further extent than liquid based chemistries, due to negligible leakage currents and the capacity to maintain much smaller charges for much longer times.

Ilika’s Stereax™ solid-state battery platform has been selected for the development effort. For bioelectronics applications of this nature batteries are charged wirelessly in situ using magnetic fields in a process known as near-field charging. The first stage of this development is being funded by Innovate UK and the Medical Research Council.

* Another blue chip endorsement of Ilika’s technology and brand. For Ilika to be selected to take part in such a high-tech development effort in bio medical science with a company established by GSK and the founders of Google is great news for the company. It is testament to Ilika’s growing reputation and brand as a global leader in the provision of high-quality, solid-state battery technology solutions in a number of disruptive markets at the onset of significant growth.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Ilika publishes 2025 Annual Report, advancing Goliath and Stereax

Ilika plc has released its 2025 Annual Report, outlining progress on Stereax licensing with Cirtec and Goliath EV battery milestones, including customer-validated P1 cells and delivery of a 50Ah prototype.

Ilika: Advancing micro-battery technology with Stereax milestone (LON:IKA)

Ilika CEO Graeme Purdy discusses the completion of manufacturing qualification for Stereax micro batteries at Cirtec’s US facility. With production underway, Ilika plans to begin customer deliveries by year-end. Purdy highlights the batteries’ compact, high-power design tailored for medical applications, and reinforces Cirtec’s strategic role in scaling commercial operations.

Ilika hits Stereax production milestone with Cirtec, Cavendish

Cavendish frames the update as a substantial de risking event. The commissioning phase in January 2025 was a vital precursor, and the latest qualification work represents the final technical validation before production.

Ilika plc Stereax Micro Batteries Enter Production with Customer Deliveries on the Horizon (Video)

CEO Graeme Purdy shares a pivotal update on the company’s Stereax micro batteries as they complete manufacturing qualification and move into production.

Ilika CEO discusses year-end results, Stereax and Goliath progress (LON:IKA)

Graeme Purdy, Ilika Plc’s Chief Executive Officer, speaks to DirectorsTalk about the company’s strong year‑end results, the strategic alignment with Cirtec for Stereax manufacturing and the latest Goliath milestones.

Ilika wins £1.25m APC grant for Goliath A-Samples (LON:IKA)

Ilika has secured £1.25m from the Advanced Propulsion Centre’s Demonstrate fund within the Government’s new £2.5bn Drive35 programme, supporting a £3m, 12-month PRIMED project with HSSMI and UKBIC to produce Goliath A-Samples.

Search

Search